Skip to main content
Julie Schallhorn, MD, Ophthalmology, Los Angeles, CA

JulieSchallhornMD

Ophthalmology • Los Angeles, CA

Cornea & External Disease, Retinal Disease, Uveitis

Assistant Professor, USC Roski Eye Institute

Join to view full profile

Dr. Schallhorn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schallhorn's full profile

Already have an account?

  • Office

    1450 San Pablo St
    Los Angeles, CA 90033
    Phone+1 503-494-7674
    Fax+1 323-442-6338

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Ophthalmology, 2010 - 2013
  • Huntington Memorial Hospital
    Huntington Memorial HospitalInternship, Transitional Year, 2009 - 2010
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 2009

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2014 - Present
  • CA State Medical License
    CA State Medical License 2010 - 2026
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Nanothin DSAEK, DMEK Yield Comparable Visual OutcomesFebruary 2019

Press Mentions

  • VA Ophthalmologist Invents Device to Help with Eye Drops
    VA Ophthalmologist Invents Device to Help with Eye DropsOctober 28th, 2024
  • Cataract Surgery After LASIK
    Cataract Surgery After LASIKDecember 9th, 2022
  • Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
    Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic ConjunctivitisOctober 26th, 2020
  • Join now to see all

Dr. Julie Schallhorn, Dr. Julie Schallhorn, MD, Dr. J Schallhorn